Lucio Phenomenon With Secondary Pseudomonas Aeruginosa Infection: One Rare Case Report
Keywords:
Lucio phenomenon, leprosy, pseudomonas aeruginosaAbstract
Introduction: Lucio phenomenon (LP) is a rare type of leprosy reaction. Lesions may begin as erythematous patches then progress to necrosis and leave fibrotic tissue. Secondary bacterial infection is common in patients with LP The organism that is commonly found is Pseudomonas aeruginosa which also found in this case. Case: A 57-year-old woman came with complaints of black and painful wounds on hands and feet since 8 weeks ago. Bilateral madarosis, saddle nose, and infiltration on auricularis region dextra-et-sinistra were found in facial examination. Multiple ulcers with a firmly bordered, irregular edge, erythem base, partially accompanied by necrotic tissue, slough, blood, pus and granulation were found in extremities examination. The chosen management are multibacillary multi-drug-therapy (MB MDT), methylprednisolone, and amikacin. The wounds were treated with NaCl and mupirocin ointment. Discussion: The main risk factor of LP is neglected leprosy infection. Secondary infection on LP is common. Management of LP with secondary infection consists of MB MDT and antibiotic base on the underlying bacterial infection. Conclusion: Lucio phenomenon is a rare severe type reaction of leprosy and associated with disability. Lucio phenomenon can occur before, during and after a complete MDT regimen. Systemic antibiotics are usually needed to treat LP with secondary infection.References
Fischer M. Leprosy – an overview of clinical features, diagnosis, and treatment. JDDG - J Ger Soc Dermatology. 2017; 15(1): 801–7.
Souza S, Maria A, Roselino F, Figueiredo F, Foss NT. Lucio’s phenomenon : Clinicai and Therapeutic Aspects’. 2000; 1(1): 68.
Ya S C, Muhamad R, Zakaria R, Ishak A, Abdullah. Lucio phenomenon: Sequelae of neglected leprosy. Korean J Fam Med. 2021; 42(5): 245–9.
World Health Organization (WHO). Leprosy (Hansen’s disease) key facts. WHO Rep. 2022; 5: 1–5.
Kemenkes RI. Hapuskan Stigma dan Diskriminasi terhadap Kusta. InfoDatin Pus Data dan Inf Kementrian Kesehat RI. 2018; 1: 1–11.
Marissa M, Rihatmadja R, Surya D, Lim H, Menaldi S. Lucio’s phenomenon: A report on six patients in a tertiary referral hospital in Indonesia. J Gen Dermatology Venereol Indones. 2020; 5: 40–7.
Miyashiro D, Cardona C, Valente NYS, Avancini J, Benard G, Trindade MAB. Ulcers in leprosy patients, an unrecognized clinical manifestation: A report of 8 cases. BMC Infect Dis. 2019; 19(2): 1–5.
Peixoto AB, Leal de C, Rodrigues NC dos S, Portela PS, Brotas AM. Fenomeno de lucio. Relato de um caso exuberante com excelente resposta ao tratamento com poliquimioterapia multibacilar. An Bras Dermatol. 2013; 88(3): 93–6.
Moronta Castellano G, Villarroel-Dorrego M, Crespo Lessmann L. Characteristics of oral lesions in patients with hansen disease. Actas Dermo-Sifiliograficas. 2020; 111: 671–7.
Sharma P, Kumar A, Tuknayat A. Lucio Phenomenon: A Rare Presentation of Hansen’s Disease. 2019; 12: 35–38.
Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia (PERDOSKI). Panduan praktik klinis bagi dokter spesialis kulit dan kelamin di indonesia. 2017; 1(1): 1-12
Herath S, Navinan MR, Liyanage I, Rathnayaka N, Yudhishdran J, Fernando J et al. Lucio’s phenomenon, an uncommon occurrence among leprosy patients in Sri Lanka. BMC Res Notes. 2015; 8(4): 4–9.
Gao W, Chen Z, Jiang H, Shi Y, Zhang W, Wang H. Diffuse multibacillary leprosy patient with Lucio’s phenomenon and positive anticardiolipin antibody misdiagnosed as lupus erythematosus panniculitis in the People’s Republic of China. Infect Drug Resist. 2019; 12(1): 741–4.
Prem Anand P, Oommen N, Sunil S, Deepa MS, Potturu M. Pretty leprosy: Another face of Hansen’s disease! A review. Egypt J Chest Dis Tuberc. 2014; 63(4): 1087–90.
Blok DJ, De Vlas SJ, Richardus JH. Global elimination of leprosy by 2020: are we. Parasites and Vectors. 2015; 8(1): 1143-4.
Pinheiro JV, Pontes MA de A, Medeiros Neto JU de, Goncalves H de S. Lucius phenomenon: the importance of a primary dermatological care. An Bras Dermatol 2022; 97(1): 54–7.
Kariosentono H, Ellistasari EY. Lucio Phenomenon : A Rare Type of Leprosy Reaction. 2022; 5(3): 253–7.
Jurado F, Rodriguez O, Novales J, Navarrete G, Rodriguez M. Lucio’s leprosy: A clinical and therapeutic challenge. Clin Dermatol. 2015; 33(1): 66–78.
Mareen J, Madhukara J. An interesting case of Lucio phenomenon triggered by activation of hepatitis C infection. Indian Dermatol Online J. 2016; 7(2): 406-7.
Alakad R, Nofal A, Assaf M. Atypical presentations of erythema nodosum leprosum: Diagnostic and therapeutic aspects. JDDG - J Ger Soc Dermatology. 2021; 19(6): 1133–43.
Khatoon S, Negi SS, Chhabra N, Bhargava A, Das P, Singh P et al. Diagnostic utility of PCR in detection of clinical cases and carriers of leprosy: A cross sectional study at a tertiary care teaching hospital in central India. Indian J Med Microbiol. 2022; 40(2): 105–8.
Swapna M, Sangeetha A V., Amudha S, Bhagat VM, Senthil Pragash D, Chadha VK. Evaluation of slit skin smear (SSS) microscopy for leprosy in various districts of Tamil Nadu. Indian J Lepr. 2021; 93(3): 85–96.
Frade MAC, Coltro PS, Filho FB, Horacio GS, Neto AA, da Silva VZ et al. Lucio’s phenomenon: A systematic literature review of definition, clinical features, histopathogenesis and management. Indian J Dermatol Venereol Leprol. 2021; 1(1): 1–14.
Saha R, Sarkar S, Majumder M, Banerjee G. Bacteriological profile of aerobic and anaerobic isolates of trophic ulcer in leprosy: A study from Eastern India. Indian J Dermatol. 2019; 64(1): 372–6.
Puspawati MD. Pseudomonas aeruginosa : infeksi kulit dan jaringan lunak. Natl Symp Dermatology Venereol. 2016; 1(1): 35-6.
Ramirez MS, Tolmasky ME. Amikacin: Uses, resistance, and prospects for inhibition. Molecules. 2017; 1(1): 22.
Sritharadol R, Hamada M, Kimura S, Ishii Y, Srichana T, Tateda K. Mupirocin at subinhibitory concentrations induces biofilm formation in staphylococcus aureus. Microb Drug Resist. 2018; 24(2): 1249–58.
(K B Kulkarni) KSP. Comparative study of topical mupirocin versus mupirocin with sucralfate combination in treatment of chronic skin ulcers. MedPulse Int J Pharmacol. 2019; 12(2): 28– 31.
